GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immatics NV (NAS:IMTX) » Definitions » Total Liabilities

Immatics NV (Immatics NV) Total Liabilities : $274.28 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Immatics NV Total Liabilities?

Immatics NV's Total Liabilities for the quarter that ended in Mar. 2024 was $274.28 Mil.

Immatics NV's quarterly Total Liabilities increased from Sep. 2023 ($202.45 Mil) to Dec. 2023 ($310.67 Mil) but then declined from Dec. 2023 ($310.67 Mil) to Mar. 2024 ($274.28 Mil).

Immatics NV's annual Total Liabilities increased from Dec. 2021 ($170.15 Mil) to Dec. 2022 ($206.20 Mil) and increased from Dec. 2022 ($206.20 Mil) to Dec. 2023 ($310.67 Mil).


Immatics NV Total Liabilities Historical Data

The historical data trend for Immatics NV's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immatics NV Total Liabilities Chart

Immatics NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial 194.57 203.48 170.15 206.20 310.67

Immatics NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 191.01 207.99 202.45 310.67 274.28

Immatics NV Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Immatics NV's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=170.722+(13.956+0.0039999999999907
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+125.984+0)
=310.67

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=556.123-245.457
=310.67

Immatics NV's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=162.07+(12.91+-1.4210854715202E-14
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+99.302+0)
=274.28

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=709.918-435.637
=274.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immatics NV Total Liabilities Related Terms

Thank you for viewing the detailed overview of Immatics NV's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Immatics NV (Immatics NV) Business Description

Traded in Other Exchanges
Address
Paul-Ehrlich-Strasse 15, Tubingen, BW, DEU, 72076
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.

Immatics NV (Immatics NV) Headlines

From GuruFocus

Immatics Announces Proposed Public Offering

By Marketwired 01-17-2024